Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Gastroparesis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Diabetic Gastroparesis - Pipeline Review, H1 2016', provides an overview of the Diabetic Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis - The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects - The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Diabetic Gastroparesis Overview 7 Therapeutics Development 8 Pipeline Products for Diabetic Gastroparesis - Overview 8 Pipeline Products for Diabetic Gastroparesis - Comparative Analysis 9 Diabetic Gastroparesis - Therapeutics under Development by Companies 10 Diabetic Gastroparesis - Therapeutics under Investigation by Universities/Institutes 11 Diabetic Gastroparesis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Diabetic Gastroparesis - Products under Development by Companies 15 Diabetic Gastroparesis - Products under Investigation by Universities/Institutes 16 Diabetic Gastroparesis - Companies Involved in Therapeutics Development 17 Cempra, Inc. 17 Evoke Pharma, Inc. 18 GlaxoSmithKline Plc 19 Ironwood Pharmaceuticals, Inc. 20 Rhythm Pharmaceuticals, Inc. 21 Shire Plc 22 Theravance Biopharma, Inc. 23 Diabetic Gastroparesis - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 camicinal - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ETX-101 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ETX-301 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 metoclopramide hydrochloride - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 prucalopride succinate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 recanaclotide - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 relamorelin - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules to Target nNOS for Diabetic Gastroparesis - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 velusetrag hydrochloride - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Diabetic Gastroparesis - Recent Pipeline Updates 47 Diabetic Gastroparesis - Dormant Projects 55 Diabetic Gastroparesis - Discontinued Products 56 Diabetic Gastroparesis - Product Development Milestones 57 Featured News & Press Releases 57 Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts 57 Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 57 Feb 17, 2016: Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 58 Sep 28, 2015: Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 58 Aug 18, 2015: Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 59 Jun 24, 2015: Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 59 May 13, 2015: Ironwood Presents Gastrointestinal Disease Research On IW-9179 at Digestive Disease Week 2015 60 Apr 14, 2015: Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001 60 Apr 09, 2015: Evoke Pharma Granted European Union Formulation Patent for EVK-001 61 Apr 08, 2015: Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 61 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for Diabetic Gastroparesis, H1 2016 8 Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Diabetic Gastroparesis - Pipeline by Cempra, Inc., H1 2016 17 Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H1 2016 18 Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H1 2016 19 Diabetic Gastroparesis - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 20 Diabetic Gastroparesis - Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016 21 Diabetic Gastroparesis - Pipeline by Shire Plc, H1 2016 22 Diabetic Gastroparesis - Pipeline by Theravance Biopharma, Inc., H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Diabetic Gastroparesis Therapeutics - Recent Pipeline Updates, H1 2016 47 Diabetic Gastroparesis - Dormant Projects, H1 2016 55 Diabetic Gastroparesis - Discontinued Products, H1 2016 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
